Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ICML 2019 | Hello TELLOMAK: new trial for T-cell lymphoma

Pierluigi Porcu • 19 Jul 2019
ICML 2019
Cutaneous T-Cell Lymphoma Lymphoma Non-Hodgkin Lymphoma Peripheral T-Cell Lymphoma Rare Diseases T-Cell Lymphoma IPH4102
TELLOMAK

Pierluigi Porcu, MD, Sidney Kimmel Cancer Center – Jefferson Health, Philadelphia, PA, discusses the current open-label, multicohort, multi-center, international Phase II TELLOMAK trial (NCT03902184), evaluating the anti-KIR3DL2 agent IPH4102 alone or with chemotherapy in advanced T-cell lymphoma. This interview took place at the 15th International Conference on Malignant Lymphoma (ICML), in Lugano, Switzerland.

More from Pierluigi Porcu

2:49
Exciting research in CTCL: genomics, the tumor microenvironment and the potential role of MRD
Pierluigi Porcu • 16 Jun 2023
3:00
The current SOC in CTCL: skin-directed therapy, systemic therapy & clinical challenges
Pierluigi Porcu • 16 Jun 2023
3:18
Lacutamab in patients with advanced mycosis fungoides: results from the TELLOMAK trial
Pierluigi Porcu • 16 Jun 2023
4:17
Nanatinostat and valganciclovir for EBV-associated lymphoma
Pierluigi Porcu • 6 Dec 2020

Related Videos

3:18
Immune-mediated bone marrow failure diseases & their pathophysiology: aplastic anemia, LR-MDS & PNH
Carlo Dufour • 15 Apr 2024
1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
1:11
Personalized risk assessment for transplantation in primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals